| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TOI | Common stock | Sale | -$18.3K | -8.64K | -100% | $2.12 | 0 | Jan 29, 2024 | See footnote | F1, F2 |
| holding | TOI | Common stock | 8.8M | Jan 29, 2024 | See footnote | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.19, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. |
| F2 | Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock. |
| F3 | TOI HC I, LLC is the record holder of these 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. The General Partner controls Havencrest Healthcare Partners, L.P. |
Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.